EUCTR2018-003890-91-PL进行中（未招募）1 期
The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds.
Medical University of Warsaw0 个研究点目标入组 100 人开始时间: 2018年11月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for Epidermolysis Bullosa Cohort:
- •1)Signed written informed consent prior to beginning study- related procedures.
- •2)Male or female:
- •a)Children, aged 5 - 18 years at date of inclusion into the study
- •b)Adults, aged 18 – 60 years at date of inclusion into the study
- •3)Established clinical diagnosis of recessive, severe, generalized type of EB (dystrophic and joint types)
- •4)Skin wound, which:
- •a)is located on the trunk or extremities,
- •b)is not healing for period of minimum 3 weeks
- •c)with a surface area between 3 – 30 cm2 (children), 10 – 30 cm2 (adults)
- •Inclusion criteria number 4) for Patients with at least two open skin wounds of similar size:
- •4)two open skin wounds of similar size (surface area difference +/– 15%), which:
- •a)are located on the trunk and/or extremities,
- •b)are not healing for period of minimum 3 weeks
- •c)each with a surface area between 3 – 30 cm2 (children), 10 – 30 cm2 (adults)
- •Inclusion Criteria for Venous Leg Ulcers Cohort:
- •1)Signed written informed consent prior to beginning study- related procedures.
- •2)Male or female, aged 40 – 80 years at date of inclusion into the study
- •3)Presence of a venous leg ulcer (VLU) between the knee and ankle:
- •a)with a surface area between: 25 cm2 - 100 cm2
- •b)that has been present for at least 3 month
- •4)Adequate circulation to the affected lower extremity, defined as an Ankle Brachial Index (ABI) greater than 0.75.
- •5)Venous insufficiency confirmed by duplex Doppler ultrasound.
- •6)Have a Clinical severity, Etiology or cause, Anatomy and Pathophysiology ulcer classification (CEAP) Grade C6: an open venous ulcer.
- •Inclusion Criteria for Thermal Injury Cohort:
- •1)Signed written informed consent prior to beginning study- related procedures.
- •2)Male or female adults, aged 18 – 60 years at date of inclusion into the study
- •3)Patient with second-degree burn (II) or third-degree burn (III) wound (s) caused by thermal injury
- •4)Target burn wound surface area: 5 – 50 cm2
- •5)The area of total burn injury below 10% TBSA.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Exclusion Criteria for Epidermolysis Bullosa Cohort:
- •1)Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures.
- •2)Chronic or current active infection or disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis B, active Hepatitis C, and known Human Immunodeficiency Virus (HIV) disease. All HIV-positive subjects are excluded from this trial
- •3)EB target wound with clinical signs (e.g. wound exudate) of local infection at day of baseline visit.
- •4)Administration of immunosuppressive agents. Use of systemic steroids within 30 days before baseline visit should be discussed with Lead Principal Investigator to determine patient’s eligibility.
- •5)Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas.
- •6)Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry.
- •7)Pregnant or nursing women.
- •Exclusion criteria for Venous Leg Ulceration Cohort:
- •1)Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures.
- •2)Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis B, active Hepatitis C, and known Human Immunodeficiency Virus (HIV) disease. All HIV-positive subjects are excluded from this trial.
- •3)Documented history of osteomyelitis at the target wound location within 6 months preceding the Baseline Visit.
- •4)Clinical evidence (e.g. wound exudate) of target ulcer infection at the day of baseline visit.
- •5)Administration of immunosuppressive agents. Use of systemic steroids within 30 days before baseline visit should be discussed with Principal Investigator to determine patient’s eligibility.
- •6)Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.
- •7)Taking, or have participated in other clinical studies involving stem cell therapy.
- •8)Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry.
- •9)Ulcer, which in the opinion of the Investigator is suspicious for cancer.
- •10)Current and/or former malignancy.
- •11)Poorly controlled type 2 diabetes mellitus defined as with glycosylated haemoglobin (HbA1c >7,0%)
- •12)Pregnant or nursing women.
- •Exclusion Criteria for Burn Cohort
- •1)Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures.
- •2)Airway burns.
- •3)Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis B, active Hepatitis C, and known Human Immunodeficiency Virus (HIV) disease. All HIV-positive subjects are excluded from this trial.
- •4)Administration of immunosuppressive agents. Use of systemic steroids within 30 days before baseline visit should be discussed with Principal Investigator to de
研究者
相似试验
尚未招募
1 期
Clinical study of Huangjin Shuangshen Granules in treating patients with anxiety and depression after coronary stent implantatioITMCTR2000003774Guang'anmen Hospital, China Academy of Chinese Medical Sciences
招募中
不适用
Integrated healthcare of new therapies through telemedicine, empowerment, gene therapeutics, registry establishment, drug safety, therapy pathways and reimbursementspinal muscular atrophy, severe combined immunodeficiency due to adenosindesamniase deficiency, metachromatic leukodystrophy, folicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, other and unspecified types of non-Hodgkin's lymphomaDRKS00030630niversitätsklinikum Heidelberg, Klinik für Hämatologie, Onkologie und Rheumatologie Innere Medizin V650
进行中（未招募）
Unknown
Investigating the effects of intravenous fluids and imatinib in human volunteers with a sepsis-like stateInfections and InfestationsSepsisISRCTN16409847Belfast Health and Social Care Trust65
已完成
不适用
Technology Assisted Programs That Promote Mental Health for TeenagersDepressionNCT01912729Northwestern University40
已完成
不适用
Participatory Action Research to Evaluate the Delivery of the MISSION ABC Service Model and Assess Health Service and Clinical OutcomesCOPDBreathlessnessAsthmaNCT03096509Portsmouth Hospitals NHS Trust342